Health Check: Telix strikes surprise $3 billion-plus headline deal to develop next-gen therapies

In a deal potentially worth more than $3 billion, radiopharmaceuticals developer Telix has struck a deal to develop next-gen cancer ... Read More The post Health Check: Telix strikes surprise $3 billion-plus headline deal to develop next-gen therapies appeared first on Stockhead .

Go to News Site